Почетна › Trostruko negativni rak dojke › Северна Каролина
Kliničke studije za Trostruko negativni rak dojke u državi Северна Каролина
22 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Северна Каролина.
Gradovi u državi Северна Каролина
Zvanični tekst studije (na engleskom)
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07069595Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Wake Forest University at Clemmons, Clemmons
- Wake Forest University Health Sciences, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03606967A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Levine Cancer Institute ( Site 0083), Charlotte
- Cape Fear Valley Health System ( Site 0136), Fayetteville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06393374Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Novant Health Cancer Institute - Elizabeth (Breast), Charlotte
- Duke Cancer Institute, Durham
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- Duke Cancer Institute, Durham
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06774027Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Duke Cancer Center /ID# 255129, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07749586The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
Тражи се учесник
Узраст 30 и старији · Жене · Ажурирано 25. 9. 2026. · NCT02945579Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT07340541Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Duke University, Durham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT05846789Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
- Wake Forest Baptist Health Sciences, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 28. 8. 2026. · NCT04677816A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Duke Cancer Institute, Durham
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Duke University Medical Center, Durham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 8. 2026. · NCT06176261Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 7. 2026. · NCT06347068Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT05005403I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- The University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 4. 2026. · NCT04468061Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 4. 2026. · NCT07276880A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 7. 1. 2026. · NCT06999187A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2025. · NCT05107674Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.